Alexza Pharmaceuticals (OTCMKTS: ALXA) and Albireo Pharma (NASDAQ:ALBO) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, profitability, earnings, institutional ownership and dividends.
Earnings & Valuation
This table compares Alexza Pharmaceuticals and Albireo Pharma’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Albireo Pharma||$11.36 million||33.40||-$4.03 million||$2.17||16.12|
Insider & Institutional Ownership
29.4% of Albireo Pharma shares are owned by institutional investors. 22.3% of Albireo Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
This table compares Alexza Pharmaceuticals and Albireo Pharma’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of current ratings and price targets for Alexza Pharmaceuticals and Albireo Pharma, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Albireo Pharma has a consensus price target of $66.67, indicating a potential upside of 90.64%.
Albireo Pharma beats Alexza Pharmaceuticals on 8 of the 8 factors compared between the two stocks.
About Alexza Pharmaceuticals
Alexza Pharmaceuticals, Inc. is a pharmaceutical company focused on the research, development and commercialization of products for the acute treatment of central nervous system conditions. The Company’s product candidates are based on the Staccato system technology. Its product candidates in development include AZ-002, which contains alprazolam as an active pharmaceutical ingredient (API) is developed for the management of patients with acute repetitive seizures, and AZ-007, which contains zaleplon as API is developed for the treatment of insomnia in patients who have difficulty falling asleep, including those patients with middle of the night awakening having difficulty falling back asleep. Its product also includes ADASUVE, which contains loxapine as API is developed for the treatment of agitation associated with schizophrenia or bipolar disorder. It has initiated a Phase IIa proof-of-concept study for AZ-002 in patients with epilepsy and has completed Phase I testing for AZ-007.
About Albireo Pharma
Biodel Inc. is a specialty biopharmaceutical company. The Company focuses on the development and commercialization of treatments for diabetes. The Company is engaged in developing product candidates by applying its formulation technologies to existing drugs. The Company is engaged in developing room temperature stable glucagon presentations for use as a rescue treatment for diabetes patients experiencing severe hypoglycemia. It also develops insulin formulations for Type 1 and Type 2 diabetes patients. Its product pipeline includes RHI-based Ultra-Rapid-Acting Insulin, Analog-based Ultra-Rapid-Acting Insulin, Concentrated Ultra-Rapid-Acting Insulin and Glucagon. The Company’s BIOD-531 is a Concentrated Ultra-Rapid-Acting Insulin and its insulin analog-based ultra-rapid-acting insulin product candidates include BIOD-123, BIOD-531, BIOD-238 and BIOD-250. It also conducts pre-clinical testing to develop liquid formulations of glucagon for hypoglycemic rescue and other indications.
Receive News & Ratings for Alexza Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexza Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.